Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR)
Pharming Group N.V. ADS is a biopharmaceutical company specializing in the development of innovative therapies for rare, unmet medical needs. The company focuses on producing recombinant protein therapies, including treatments for genetically defined diseases and conditions involving enzyme deficiencies. Pharming is known for its flagship product, Rapyda, used in the treatment of hereditary angioedema. The company's operations are centered around developing and commercializing biologic medicines for patients worldwide.
Company News
Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global finance leadership experience in life sciences, previously serving as CFO at Schoeller Allibert, Zentiva, and holding senior roles at Gilead Sciences.
Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. Impinj, Inc. (NASDAQ: PI) shares rose 31% to $65.06 after the company reported better-than-expected third-quarter revenue results. Bel Fuse Inc. (NASDAQ: BELFB) surged 23...